Cargando…

Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect?

The ChAdOx1 nCoV-19 vector vaccine (Vaxzevria, AstraZeneca, Cambridge, UK) was developed at Oxford University and is considered safe for the administration in lactating mothers. Nevertheless, as a novel vaccine, there are gaps in the knowledge regarding possible adverse events in breastfeeding infan...

Descripción completa

Detalles Bibliográficos
Autores principales: Diogo, Patrícia, Correia, Gil, Martins, João B., Soares, Rui, Palma, Paulo J., Santos, João Miguel, Gonçalves, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031970/
https://www.ncbi.nlm.nih.gov/pubmed/35455352
http://dx.doi.org/10.3390/vaccines10040602
_version_ 1784692524533678080
author Diogo, Patrícia
Correia, Gil
Martins, João B.
Soares, Rui
Palma, Paulo J.
Santos, João Miguel
Gonçalves, Teresa
author_facet Diogo, Patrícia
Correia, Gil
Martins, João B.
Soares, Rui
Palma, Paulo J.
Santos, João Miguel
Gonçalves, Teresa
author_sort Diogo, Patrícia
collection PubMed
description The ChAdOx1 nCoV-19 vector vaccine (Vaxzevria, AstraZeneca, Cambridge, UK) was developed at Oxford University and is considered safe for the administration in lactating mothers. Nevertheless, as a novel vaccine, there are gaps in the knowledge regarding possible adverse events in breastfeeding infants of vaccinated mothers. This case report provides first-time data on a possible delayed, cutaneous, adverse reaction in a breastfed, 16-month-old female infant after the first administration of the AstraZeneca vaccine to her 33-year-old mother. Even though, no clinical adverse effects were observed in the mother, her daughter had a 2-day rash in the lower extremities and face. The infant’s cutaneous rashes might be a coincidental event. However, all skin lesions were analogous to previous descriptions and photographs of dermatologic reactions, which resolved spontaneously with no medical intervention, in people who had been vaccinated with other COVID-19 vaccines. Our aim is that this short report contributes to the enhancement of parental awareness about the possibility of similar skin rashes in breastfed children when the mothers receive a vaccination and the importance of reporting those adverse reactions to the competent authorities.
format Online
Article
Text
id pubmed-9031970
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90319702022-04-23 Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect? Diogo, Patrícia Correia, Gil Martins, João B. Soares, Rui Palma, Paulo J. Santos, João Miguel Gonçalves, Teresa Vaccines (Basel) Case Report The ChAdOx1 nCoV-19 vector vaccine (Vaxzevria, AstraZeneca, Cambridge, UK) was developed at Oxford University and is considered safe for the administration in lactating mothers. Nevertheless, as a novel vaccine, there are gaps in the knowledge regarding possible adverse events in breastfeeding infants of vaccinated mothers. This case report provides first-time data on a possible delayed, cutaneous, adverse reaction in a breastfed, 16-month-old female infant after the first administration of the AstraZeneca vaccine to her 33-year-old mother. Even though, no clinical adverse effects were observed in the mother, her daughter had a 2-day rash in the lower extremities and face. The infant’s cutaneous rashes might be a coincidental event. However, all skin lesions were analogous to previous descriptions and photographs of dermatologic reactions, which resolved spontaneously with no medical intervention, in people who had been vaccinated with other COVID-19 vaccines. Our aim is that this short report contributes to the enhancement of parental awareness about the possibility of similar skin rashes in breastfed children when the mothers receive a vaccination and the importance of reporting those adverse reactions to the competent authorities. MDPI 2022-04-13 /pmc/articles/PMC9031970/ /pubmed/35455352 http://dx.doi.org/10.3390/vaccines10040602 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Diogo, Patrícia
Correia, Gil
Martins, João B.
Soares, Rui
Palma, Paulo J.
Santos, João Miguel
Gonçalves, Teresa
Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect?
title Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect?
title_full Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect?
title_fullStr Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect?
title_full_unstemmed Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect?
title_short Delayed Cutaneous Adverse Reaction of the AstraZeneca COVID-19 Vaccine in a Breastfed Female Infant: A Coincidence or a Rare Effect?
title_sort delayed cutaneous adverse reaction of the astrazeneca covid-19 vaccine in a breastfed female infant: a coincidence or a rare effect?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031970/
https://www.ncbi.nlm.nih.gov/pubmed/35455352
http://dx.doi.org/10.3390/vaccines10040602
work_keys_str_mv AT diogopatricia delayedcutaneousadversereactionoftheastrazenecacovid19vaccineinabreastfedfemaleinfantacoincidenceorarareeffect
AT correiagil delayedcutaneousadversereactionoftheastrazenecacovid19vaccineinabreastfedfemaleinfantacoincidenceorarareeffect
AT martinsjoaob delayedcutaneousadversereactionoftheastrazenecacovid19vaccineinabreastfedfemaleinfantacoincidenceorarareeffect
AT soaresrui delayedcutaneousadversereactionoftheastrazenecacovid19vaccineinabreastfedfemaleinfantacoincidenceorarareeffect
AT palmapauloj delayedcutaneousadversereactionoftheastrazenecacovid19vaccineinabreastfedfemaleinfantacoincidenceorarareeffect
AT santosjoaomiguel delayedcutaneousadversereactionoftheastrazenecacovid19vaccineinabreastfedfemaleinfantacoincidenceorarareeffect
AT goncalvesteresa delayedcutaneousadversereactionoftheastrazenecacovid19vaccineinabreastfedfemaleinfantacoincidenceorarareeffect